Beam Therapeutics, Inc. (BEAM)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$29.66+0.68%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · BEAM
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 41.9% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| -53.9% |
Growth built into the price is above our model estimate.
The price assumes 95.7 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name has erratic recent earnings surprises and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
BEAM — earnings miss
Dated 2026-08-04
as well as in the accompanying Exhibit 99.1 attached hereto is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company, under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Why it matters: Initial data could show the potential of BEAM-301 in treating GSDIa. Positive results may enhance Beam's portfolio.
Supportive ifInitial clinical data for BEAM-301 will be reported in 2026.
Worry ifNo data released or negative results from the BEAM-301 trial.
Why it matters: Getting funding is key for Beam's work and growth. It affects investor trust.
Supportive ifAnnouncement of a financing deal worth at least $50M.
Worry ifNo financing announcement by the next earnings date.
Why it matters: Expanding the product portfolio can drive future growth. It shows progress in innovation.
Supportive ifAnnouncement of at least two new base editing products or partnerships.
Worry ifNo news about portfolio expansion in the next quarter.
Why it matters: Starting this trial is key for Beam's lead program in AATD. It shows progress toward a potential treatment.
Supportive ifAnnouncement of the initiation of the pivotal cohort for BEAM-302 in AATD.
Worry ifNo announcement about starting the important group by the end of 2026.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$267 on $10,000 · ±2.7% | How much price usually moves either way. |
| Bad day | $664 loss on $10,000 · 6.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,815 loss on $10,000 · 38.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Maintaining a strong cash position is vital for funding operations and clinical trials. Any changes could impact future plans.
Worry ifThe cash position stays steady or improves. This supports operations until mid-2029.
Less concerning ifCash position drops a lot or funding is unclear.
Why it matters: Getting financing is key for paying bills. This impacts long-term success.
Supportive ifNew financing or partnership announced. This helps extend funds into 2029.
Worry ifNo financing secured, raising concerns about cash flow.
Why it matters: High operating losses could signal trouble in managing costs. Investors watch for signs of financial health.
Worry ifQ2 operating losses reported worse than -$100M.
Less concerning ifQ2 operating losses were better than -$100M.
Why it matters: Starting this trial is crucial for demonstrating Beam's base editing technology in a new indication. It could expand their treatment options.
Supportive ifThe Phase 1/2 trial for BEAM-304 begins as planned.
Worry ifThe trial start is delayed or canceled.
Why it matters: Filing the IND is crucial for advancing BEAM-304, which targets PKU and expands Beam's portfolio.
Supportive ifAnnouncement of the IND application filing for BEAM-304 with the FDA.
Worry ifNo IND filing for BEAM-304 by the end of 2026.
Why it matters: Submitting the BLA is a key step toward bringing risto-cel to market for sickle cell disease. This could enhance Beam's market position.
Supportive ifThe BLA submission for risto-cel will be done by December 2026.
Worry ifSubmission is delayed beyond year-end 2026.
Why it matters: If the sector grows again, it could help Beam's performance and future.
Supportive ifHealth Care sector revenue growth speeds up to 10% or more.
Worry ifSector revenue growth keeps slowing down to less than 5%.